2015
Grant & Award Recipients
Together, we're taking down cancer.
Toget her, we’re taking it down.

Conquer Cancer Foundation donors are invited to relax in the Donor Lounge, S401.

Not yet a donor? Text **CONQUER** to 41444* to make your donation today!

A suggested cumulative annual contribution of $250 or more is appreciated.

ccf.asco.org
#ConquerCancer

*Message and data rates may apply.
Terms: igfn.org/t. Text STOP to 41444 to stop. Text HELP to 41444 for help.
A series of four reminder messages will be sent until donation is completed.
Message from the Conquer Cancer Foundation Chair

We use the word “impact” often at the Conquer Cancer Foundation—and with good reason. In the end, impact is what matters the most: How effectively are we, as a Foundation, contributing to progress against cancer on behalf of our generous donors?

There are different ways to measure impact, and when it comes to our Grants and Awards Program there is plenty of impressive data to share. Since 1984, more than $90 million in research funding has been awarded to over 1,000 promising physician-scientists. Ninety-nine percent of grant and award recipients report that their grant was important in the support and advancement of their careers.

These statistics are certainly powerful and encouraging. What I find so meaningful about the Conquer Cancer Foundation Grants & Awards Ceremony is the chance to interact with the people behind the numbers: the passionate, dedicated researchers who strive every day to help conquer cancer, and whose work—without our support—might not be possible. Indeed, this ceremony is a wonderful opportunity to view our collective impact in action.

The Conquer Cancer Foundation announced its first-ever campaign this week at the ASCO Annual Meeting. We are incredibly excited about The Campaign to Conquer Cancer: for the funds that it will help us raise; for the awareness that it will garner; and, most importantly, for the impact that it will have as we work toward our ultimate goal—a world free from the fear of cancer. Thank you for taking part in this important moment.

Additional thanks are in order: to the members of our Grant Selection Committees, whose expertise and thorough work ensures we continue to fund only the best and brightest in cancer research; to our donors, whose generous and loyal support makes all of our achievements possible; and, of course, to our 2015 grant and award recipients. Thank you for bringing your talents and time to the challenging field of cancer research. We look forward to your research accomplishments, and to the IMPACT that your work will have for patients with cancer, their families, and the future of cancer research.

Best regards,

W. Charles Penley, MD, FASCO
Chair, Conquer Cancer Foundation
# Table of Contents

Message from the Conquer Cancer Foundation Chair  
Young Investigator Award  
Career Development Award  
Advanced Clinical Research Award  
Research Professorships  
Clinical Trials Participation Awards  
Resident Travel Award  
Medical Student Rotation Award  
Grants and Awards Funding Map  
International Programs  
Long-term International Fellowship  
International Development and Education Award  
International Innovation Grant  
Merit Awards  
Boards of Directors  
Grants Selection Committee  
Conquer Cancer Foundation Staff  
Program Supporters  
Top Donor Recognition Awards
Conquer Cancer Foundation—Who We Are

We are a nonprofit organization created in 1999 by the world’s foremost cancer doctors, the American Society of Clinical Oncology (ASCO) to seek dramatic advances in the prevention, diagnosis, treatment and cure of all types of cancer. We are the only cancer foundation backed by the expertise of the world’s leading cancer physicians—the most trusted and credible source of cancer knowledge, education, and information. These cancer professionals care for, listen to and learn from cancer patients every day.

With your help we fund a wide range of research initiatives that provide insight into virtually every aspect of cancer, from prevention and diagnosis to treatment and survivorship.

The Foundation’s mission to conquer all types of cancer is advanced through:

- **Investing in the careers of young investigators and in promising research** that will yield new insights and improve cancer knowledge and expertise through our Grants and Awards Program
- **Improving quality and access to care** by unlocking and analyzing cancer care data and feeding up-to-the minute conclusions and guidance back to physicians and patients through a ground-breaking health information system called CancerLinQ™
- **Empowering patients, families, and caregivers** by giving them 24/7 access to comprehensive, accurate, oncologist-approved information for over 120+ cancer types through patient

#ConquerCancer

Connect with the Conquer Cancer Foundation on Social Media

Conquer Cancer Foundation

@iConquer Cancer

Conquer Cancer Foundation of ASCO

ConquerCancerFdtn
Young Investigator Awards

First awarded in 1984, the YIA provides research funding to promising young physicians during the final years of training to support the transition to a faculty appointment and to encourage quality research in clinical oncology.

2015 RECIPIENTS

**Daniel H. Ahn, DO**  
*The Ohio State University*  
“Combined Inhibition of PI3K/Akt and MAPK Pathways in Advanced Biliary Cancer”  
Supported by: The Cholangiocarcinoma Foundation  
Mentored by: Tanios Bekaii-Saab, MD

**Ali Imran Amjad, MBBS, MD**  
*University of Pittsburgh*  
“A Pilot Placebo-Controlled Randomized Study of Biomarker Modulation with Sulforaphane-rich Broccoli Sprout Extract in Patients with Prostate Cancer”  
Supported by: Conquer Cancer Foundation  
Mentored by: Rahul Parikh, PhD, MBBS, Shivendra Singh, PhD

**Mark M. Awad, MD, PhD**  
*Dana-Farber Cancer Institute*  
“Clinical and Genomic Correlates of PD-1, PD-L1, and PD-L2 Expression in Non-Small Cell Lung Cancer”  
Supported by: Conquer Cancer Foundation  
Mentored by: Pasi Janne, MD, PhD (2001 YIA)

**Pavan Bachireddy, MD**  
*Dana-Farber Cancer Institute*  
“Single cell transcriptome sequencing of intratumoral T cells to dissect clinical immunotherapeutic response and resistance”  
Mentored by: Catherine Wu, MD

**Adam Richard Belanger, MD**  
*University of North Carolina at Chapel Hill*  
“Molecular Drivers of Lymphatic Metastasis in Lung Squamous Cell Carcinoma”  
Mentored by: Chad Pecot, MD (2011 YIA)

**Melissa A. Burns, MD**  
*Dana-Farber Cancer Institute*  
“Smoothened as a Therapeutic Target in High Risk T-cell Acute Lymphoblastic Leukemia”  
Supported by: Strike 3 Foundation  
Mentored by: Alejandro Gutierrez, MD, Thomas Look, MD

**Matthew T. Campbell, MD**  
*The University of Texas MD Anderson Cancer Center*  
“Enhancing therapeutic efficacy in metastatic renal cell carcinoma by combining immune check point blockade with cryoablation.”  
Supported by: Kidney Cancer Association  
Mentored by: Padmanee Sharma, MD, PhD (2003 YIA, 2006 CDA)

**Lan Gardner Coffman, MD, PhD**  
*The University of Michigan*  
“Defining the origin and role of carcinoma-associated mesenchymal stem cells in the ovarian cancer microenvironment”  
Mentored by: Ronald Buckanovich, MD, PhD

FROM 1984-2015:

**894**  
YIA Recipients

**Over**  
$36.9 Million  
YIA Research Funding
Natalie Bucheimer Collins, MD, PhD
Dana-Farber Cancer Institute
“Defining Molecular Mechanisms of Resistance to Tumor Immunity”
Mentored by: W. Nicholas Haining, MD (2000 CDA)

Cristina Cruz, MD, PhD
Vall d’Hebron Institute of Oncology
“Identification of BRCA mRNA Isoforms that Generate Proteins with Functional Capacity, as a Potential Novel Mechanism of Resistance Against PARP Inhibitors in Germline BRCA Mutant Breast Cancer (BC)”
Supported by: Conquer Cancer Foundation
Mentored by: Judith Balmana Gelpi, MD, PhD

William Brian Dalton, MD, PhD
Johns Hopkins University
“The Role of SF3B1 Mutation in Breast Cancer”
Supported by: Breast Cancer Research Foundation®, in honor of Susan Hirschhorn and in memory of her mother
Mentored by: Ben Park, MD, PhD

Helen Dinkelspiel, MD
Columbia University Medical Center
“Influence of geographic variation on access to minimally invasive gynecologic cancer surgery”
Supported by: Young A. Sohn and Mark Armenante
Mentored by: Jason Wright, MD

Daniel Nathan Egan, MD
Fred Hutchinson Cancer Research Center
“Biology of Non-Response to Induction Therapy in Adult AML”
Supported by: Conquer Cancer Foundation
Mentored by: Jerald Radich, MD

Yasir Y. Elamin, MBBS
The Royal College of Surgeons in Ireland
“The role of Protein Tyrosine Phosphatase non-Receptor type 11 (PTPN11/Shp2) mutations in human non-small cell lung cancer (NSCLC)”
Supported by: Conquer Cancer Foundation
Mentored by: Bryan Hennessy, MD (2007 YIA, 2008 CDA)

Christian Gocke, MD, PhD
Johns Hopkins University
“Improving outcomes in multiple myeloma through a better understanding of oncogenic RAS signaling”
Mentored by: William Matsui, MD (2001 YIA, 2004 CDA)

Jennifer Brooke Goldstein, MD
The University of Texas MD Anderson Cancer Center
“Clonal Evolution of Glioblastoma”
Mentored by: Andrew Futreal, MD

John Gordan, MD, PhD
University of California, San Francisco
“Developing RICTOR amplification as a predictive biomarker of mTOR inhibitor sensitivity in hepatocellular carcinoma”
Supported by: The Scopus Foundation
Mentored by: Keven Shokat, PhD

Scott M. Haake, MD
H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida
“The Impact of Collagen on Renal Cell Carcinoma Growth and Drug Resistance”
Supported by: Conquer Cancer Foundation
Mentored by: Eric Haura, MD (2007 ACRA), W. Rathmell, MD, PhD, Mayer Fishman, MD, PhD
Jonathan Matthew Hernandez, MD
Memorial Sloan Kettering Cancer Center
“Interrogation of exosome-mediated intercellular signaling in patients with pancreatic adenocarcinoma”
Mentored by: Willian Jarnagin, MD, David Lyden, MD, PhD

Valerie Malyvanh Jansen, MD, PhD
Vanderbilt University Medical Center
“Co-targeting the CDK4/6 pathway in hormone receptor positive breast cancer”
Supported by: Breast Cancer Research Foundation®
Mentored by: Carlos Arteaga, MD

Matko Kalac, MD, PhD
Columbia University Medical Center
“Translational Development of Novel Small Molecules Targeting NF-κB pathway for the Treatment of Diffuse Large B-Cell Lymphoma”
Mentored by: Owen O’Connor, MD, PhD

Michael Sangmin Lee, MD
The University of Texas MD Anderson Cancer Center
“Combination CDK4/6 inhibitor and MEK inhibitor in KRAS mutant metastatic colorectal cancer”
Mentored by: Scott Kopetz, MD, PhD (2008 CDA)

Jonathan Merle Lehman, MD, PhD
Vanderbilt University Medical Center
“Targeting Somatostatin Receptor 2 Signaling in Lung Cancer”
Mentored by: Pierre Massion, MD (2007 ACRA)

Loretta Sze-Mun Li, MD
Dana-Farber Cancer Institute
“Defining Mechanisms of Resistance to Type II JAK2 Inhibitors in B-cell Acute Lymphoblastic Leukemia (B-ALL)”
Supported by: Strike 3 Foundation
Mentored by: David Weinstock, MD (2006 YIA)

Jyoti Malhotra, MD, MPH
Mount Sinai School of Medicine
“Genetic Susceptibility to Small Cell Lung Cancer Risk”
Mentored by: Paolo Boffetta, MD, MPH

Gulam Abbas Manji, MD, PhD
Columbia University Medical Center
“Preclinical evaluation of combination immunotherapy approaches for pancreatic ductal adenocarcinoma”
Supported by: Conquer Cancer Foundation
Mentored by: Kenneth Olive, PhD

Mark C. Markowski, MD, PhD
Johns Hopkins University
“Effect of PTEN Loss on Combination PI3K inhibition, Castration, and Radiation in Clinically Localized, Aggressive Castration Sensitive Prostate Cancer.”
Mentored by: Angelo De Marzo, MD, PhD

Benjamin Louis Maughan, MD
Johns Hopkins University
“The role of AR splice variant-7 and Rb loss in predicting chemotherapy response in men with primary resistance to abiraterone or enzalutamide.”
Mentored by: Emmanuel Antonarakis, MD (2009 YIA), Tamara Lotan, MD

Shannon Rose McCurdy, MD
Johns Hopkins University
“Development of Pharmacodynamic Markers for Therapeutic Co-Inhibitory Blockade after Allogeneic Bone Marrow Transplantation”
Mentored by: Leo Luznik, MD
Jennifer Leigh McQuade, MD  
The University of Texas MD Anderson Cancer Center  
“The impact of energy balance and the insulin/IGF axis on resistance to targeted therapy in melanoma”  
Mentored by: Michael Davies, MD, PhD (2005 YIA, 2010 CDA)

David Jesse Mulvihill, MD  
Rutgers, The State University of New Jersey  
“Childhood Radiation Exposure From Interventional Cardiology Procedures And Subsequent Cancer Risk”  
Mentored by: John Kostis, MD

Prabhjot S. Mundi, MD  
Columbia University Medical Center  
“Targeting computationally inferred master regulators in patient derived xenografts from patients with operable breast cancer.”  
Supported by: Breast Cancer Research Foundation®  
Mentored by: Andrea Califano, MD

Mark Alan Murakami, MD  
Dana-Farber Cancer Institute  
“Overcoming resistance in BCR-ABL-rearranged acute lymphoblastic leukemia.”  
Mentored by: David Weinstock, MD (2006 YIA)

Mrs. Evelyn H. Lauder  
(1936–2011)  
Evelyn H. Lauder was passionate about funding breast cancer research and focusing global awareness on women’s health. She is best known for her career of more than 50 years with The Estée Lauder Companies, and as Founder of the Breast Cancer Research Foundation® (BCRF). In 1989, the Evelyn H. Lauder Breast Center at Memorial Sloan-Kettering Cancer Center was established as the first-ever breast and diagnostic center. A new and greatly enlarged Center opened in 2009. In October 1992, Mrs. Lauder launched the Pink Ribbon as the worldwide symbol of breast health; since then, more than 135 million pink ribbons have been distributed by The Estée Lauder Companies. In 1993, she established BCRF, which has raised over $500 million for breast cancer research worldwide. Among many honors, she received France’s Chevalier of the Legion of Honor (2002) and the ASCO Partners in Progress Award (2007). Mrs. Lauder was a recognized photographer whose art is exhibited internationally. She published two books of photographs and a cookbook, with all royalties donated to BCRF.

Kara N. Maxwell, MD, PhD  
University of Pennsylvania  
“Identification of novel genetic determinants of breast cancer susceptibility in BRCA1/2 negative patients with familial breast cancer”  
Mentored by: Katherine Nathanson, MD

SUPPORTED BY  
The Evelyn H. Lauder YIA Endowment Fund

BCRF
**David B. Page, MD**  
Memorial Sloan Kettering Cancer Center  
“T-cell receptor DNA deep sequencing as a novel immune-based biomarker in early stage breast cancer”  
**Supported by:** Breast Cancer Research Foundation®  
**Mentored by:** Jedd Wolchok, MD, PhD

**Anthony Joseph Paravati, MD, MBA**  
University of California, San Diego  
“An individualized patient-specific risk assessment tool to predict non-cancer and prostate cancer mortality in elderly men with prostate cancer”  
**Mentored by:** Arno Mundt, MD

**Robin Parihar, MD, PhD**  
Baylor College of Medicine  
“Enhancement of NK cell cytotoxicity against myeloid-derived suppressor cells in a novel xenograft model of pediatric cancer”  
**Mentored by:** David Poplack, MD

**Eirini Pectasides, MD**  
Dana-Farber Cancer Institute  
“Genomic Heterogeneity: A Barrier to Biomarker Profiling and Targeted Therapy for Gastroesophageal Cancer”  
**Mentored by:** Adam Bass, MD

**Jonathan Peled, MD, PhD**  
Memorial Sloan Kettering Cancer Center  
“The role of microbiota on graft-versus-tumor activity in hematological malignancies”  
**Mentored by:** Marcel van den Brink, MD, PhD

**Lara Ann Dunn, MD**  
Memorial Sloan Kettering Cancer Center  
“Enhancing Radioactive Iodine (RAI) Incorporation into BRAF-mutant, RAI-Refractory Thyroid Cancers with Vemurafenib in Combination with the Anti-HER3 Monoclonal Antibody KTN3379: A Pilot Study”  
**Mentored by:** David Pfister, MD

**Nitya Prabhakar Raj, MD**  
Memorial Sloan Kettering Cancer Center  
“Mechanisms of acquired resistance to everolimus in metastatic well differentiated pancreatic neuroendocrine tumors”  
**Mentored by:** Diane Reidy-Lagunes, MD (2008 YIA)

**David Ronan Raleigh, MD, PhD**  
University of California, San Francisco  
“Understanding Gli2 activation of Hedgehog target genes in medulloblastoma”  
**Mentored by:** Jeremy Reiter, MD, PhD

**Bob Li, MBBS, MPH**  
Memorial Sloan Kettering Cancer Center  
“Ado-trastuzumab emtansine for HER2 amplified or HER2 overexpressed cancers: A phase 2 “basket” trial”  
**Mentored by:** Mark Kris, MD

**SUPPORTED BY**  
The Sally Gordon YIA Endowment Fund
Zuzana Tothova, MD, PhD  
*Dana-Farber Cancer Institute*  
“Investigating mechanisms of cohesin-mediated leukemogenesis in MDS and AML”  
Mentored by: Benjamin Ebert, MD, PhD

SUPPORTED BY  
ASCO and Conquer Cancer Foundation  
Boards of Directors

Jorge Daniel Ramos, DO  
*University of Washington*  
“PET/CT for assessment of treatment response and direction of metastatic biopsies for characterization of the DNA damage response pathway as a possible mechanism of resistance to Radium-223 in metastatic castration resistant prostate cancer”  
Supported by: Conquer Cancer Foundation  
Mentored by: Evan Yu, MD

Saleha Sajid, MBBS, MD  
*The University of Chicago*  
“Physical Activity Interventions in Older Prostate Cancer Patients on Potent Androgen Ablation (PAA) Therapy: A Randomized Pilot Study”  
Mentored by: William Dale, MD, PhD

Eric L. Smith, MD, PhD  
*Memorial Sloan Kettering Cancer Center*  
“Additional genetic modification of CAR T cells to secrete the proinflammatory cytokine IL12 as a method to prevent post-CAR T cell relapse”  
Mentored by: Renier Brentjens, MD, PhD

Elizabeth Harmon Stover, MD, PhD  
*Dana-Farber Cancer Institute*  
“Mechanisms of platinum resistance in high-grade serous ovarian cancer”  
Supported by: Conquer Cancer Foundation  
Mentored by: Levi Garraway, MD, PhD

CONQUER CANCER FOUNDATION OF ASCO JANE C. WRIGHT, MD YOUNG INVESTIGATOR AWARD

John R. Durant, MD (1930-2012)  
Dr. Durant’s generous nature and steadfast commitment to improving the lives of people with cancer were reflected throughout his career. Dr. Durant was the Founding Director of the UAB Comprehensive Cancer Center, President and CEO of the Fox Chase Cancer Center in Philadelphia, was the ASCO President from 1985-1986, and in 1995, he became ASCO’s first Executive Vice-President. Dr. Durant has left an indelible mark on the Society. Everything that ASCO does today is built on the foundation that he established, and everyone who enjoyed the privilege of working with him will remember the passion he showed for his work, the patients he served, his family, and the organization.

Enrique Soto Perez de Celis, MD  
*Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran*  
“A Pilot Study of a Mobile Sensor-Based System for the Remote Monitoring of Functional Status in Older Adults with Cancer Receiving Chemotherapy in a Developing Country”  
Mentored by: Alvaro Aguayo, MD

SUPPORTED BY  
The John R. Durant, MD, YIA Endowment Fund

Supported by: Conquer Cancer Foundation

Mentored by: Levi Garraway, MD, PhD
Conquer Cancer Foundation

Mission Endowment

Conquer Cancer Foundation of ASCO Young Investigator Award Supported by Women Who Conquer Cancer

The Conquer Cancer Foundation would like to extend special thanks to the Women Who Conquer Cancer donors, whose generous contributions are supporting a 2015 Young Investigator Award. We salute their commitment to help ensure that there will be a talented cohort of scientists hard at work improving cancer care for decades to come.


Alexandra Snyder Charen, MD
Memorial Sloan Kettering Cancer Center
“Tumor Neoantigens and the Response to Checkpoint Blockade in Metastatic Melanoma”
Mentored by: Timothy Chan, MD, PhD (2007 YIA)

Benjamin Addison Teply, MD, MS
Johns Hopkins University
“Glucocorticoid receptor expression as a targetable biomarker in metastatic castration resistant prostate cancer.”
Mentored by: Samuel Denmeade, MD

Michelle Treasure, MD
Case Western Reserve University
“A Pilot Study of Structured Palliative Care for Patients Enrolled on Phase I Clinical Trials”
Supported by: Conquer Cancer Foundation
Mentored by: Neal Meropol, MD

Kristina Marie Vander Wall, MD
University of California, Los Angeles
“Novel Assessment of Performance Status and Functional Decline in Elderly Cancer Patients on Cytotoxic Therapy: Building a “Smart Clinical Home” Using Ambient Sensors and a Personal Remote Monitoring Device”
Supported by: ASCO State Affiliate Council and ASCO Clinical Practice Committee
Mentored by: Arash Naeim, MD, PhD (2002 YIA)

Aaron David Viny, MD, MS
Memorial Sloan Kettering Cancer Center
“The Cohesin Complex in Leukemic Transformation”
Mentored by: Ross Levine, MD (2006 YIA)

Kristina Hoot Young, MD, PhD
Providence Portland Medical Center
“Targeting the tumor stroma to enhance radiation efficacy”
Mentored by: Marka Critttenden, MD, PhD

Jianjun Zhang, MD, PhD
The University of Texas MD Anderson Cancer Center
“The impact of intra-tumor heterogeneity on disease-free survival after complete resection in patients with stage I lung adenocarcinomas”
Mentored by: Andrew Futreal, PhD
Career Development Award

Started in 1992, the CDA provides research funding to clinical investigators in the first to third year of faculty appointment to establish an independent clinical cancer research program.

2015 RECIPIENTS

Sandra Pierina D’Angelo, MD
Memorial Sloan Kettering Cancer Center
“Identifying biomarkers predictive of response to nivolumab +/- ipilimumab in patients with metastatic sarcoma.”
Supported by: Conquer Cancer Foundation Mission Endowment
Mentored by: William Tap, MD

Ayca Gucalp, MD
Memorial Sloan Kettering Cancer Center
“A Randomized Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Disease”
Supported by: Conquer Cancer Foundation Mission Endowment
Mentored by: Clifford Hudis, MD

Siwen Hu-Lieskovan, MD, PhD
David Geffen School of Medicine at UCLA
“Mechanistic study of double immune suppression blockade combining CSF-1R inhibitor PLX3397 with anti-PD-1 antibody pembrolizumab to treat advanced melanoma/solid tumors”
Mentored by: Antoni Ribas, MD, PhD (2000 CDA)

Douglas Buckner Johnson, MD
Vanderbilt University Medical Center
“Optimizing targeted and immune therapy approaches for non-BRAF V600 melanoma”
Mentored by: Jeffrey Sosman, MD

David Margel, MD, PhD
Rabin Medical Center
“Personalized prostate cancer screening among male BRCA carriers - a prospective cohort study”
Mentored by: Baruch Brenner, MD

Sean Matthew McBride, MD, MPH
Memorial Sloan Kettering Cancer Center
“A Phase II Randomized Controlled Screening Trial of Nivolumab with Image Guided, Stereotactic Body Radiotherapy (SBRT) versus Nivolumab Alone in Patients with Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Received Previous Platinum Therapy”
Mentored by: Nancy Lee, MD

Katherine Elizabeth Reeder-Hayes, MD, MBA
University of North Carolina at Chapel Hill
“Adoption of Breast Cancer Gene Expression Profiling, Effects on Chemotherapy Utilization and Disease Outcomes”
Supported by: Breast Cancer Research Foundation®
Mentored by: Ethan Basch, MD, MSc (2007 CDA)

Rizwan Romee, MD
Washington University
“A phase 1 study of cytokine induced memory-like NK cells in patients with relapsed and refractory AML”
Mentored by: John DiPersio, MD, PhD, Todd Fehniger, MD, PhD (2007 YIA)

“This was my first major grant and has been a major stepping stone.”

—Dr. Hermant Roy
University of Chicago
1996 CDA
Florian Rudolf Schroeck, MD, MS  
*White River Junction VA Medical Center/ The Dartmouth Institute*  
“Understanding Risk-Aligned Care for Early Stage Bladder Cancer”  
**Supported by:** Conquer Cancer Foundation Mission Endowment  
**Mentored by:** Philip Goodney, MD, Todd MacKenzie, PhD

Vamsidhar Velcheti, MD (2012 YIA)  
*The Cleveland Clinic*  
“Novel Pharmacologic approach to enhance the epigenetic and immune priming effect of decitabine in patients with advanced non-small cell lung cancer”  
**Mentored by:** Afshin Dowlati, MD, Roy Herbst, MD, PhD (1997 YIA, 1999 CDA), Yogen Saunthararajah, MD

Jason R. Westin, MD (2012 YIA)  
*The University of Texas MD Anderson Cancer Center*  
“Smart Start: A Phase Ib/II Study of Rituximab, Lenalidomide, Ibrutinib and EPOCH in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma”  
**Mentored by:** R. Eric Davis, MD, Sattva Neelapu, MD (2006 CDA)

---

**SUPPORTED BY**

- **astellas ONCOLOGY**  
  Changing Tomorrow in Cancer Care
- **AstraZeneca**
- **BCRF**  
  BREAST CANCER RESEARCH FOUNDATION
- **CONQUER CANCER FOUNDATION**  
  MISSION ENDOWMENT
- **Genentech**  
  A Member of the Roche Group
- **Lilly**  
  ONCOLOGY
- **Takeda**  
  ONCOLOGY

*As of April 29, 2015*
Advanced Clinical Research Award

Started in 2004, the ACRA supports physician-scientists in the fourth to ninth year of faculty appointment to perform original research in an area not currently funded.

2015 ACRA IN BREAST CANCER RECIPIENT

Priyanka Sharma, MD
University of Kansas Medical Center
“Evaluation of BRCAness phenotype as prognostic marker in triple-negative breast cancer”

SUPPORTED BY

Number of ACRAs we have awarded:

11 in Breast Cancer
1 in Hematologic Malignancies
2 in Lung Cancer
3 in Sarcoma
1 in Colorectal Cancer
1 in Glioma
Research Professorships

Started in 2009, Research Professorships provide flexible funding to outstanding researchers who have made and are continuing to make significant contributions that have changed the direction of cancer research and who provide mentorship to junior researchers.

**COMPARATIVE EFFECTIVENESS RESEARCH PROFESSOR**

<table>
<thead>
<tr>
<th>Professor</th>
<th>Institution</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dawn L. Hershman, MD, MS</td>
<td>Columbia University Medical Center</td>
<td>“Reducing Overuse and Underuse to Improve the Quality and Safety of Breast Cancer Care”</td>
</tr>
<tr>
<td>Patricia A. Ganz, MD, FASCO</td>
<td>University of California, Los Angeles</td>
<td>“Improving Outcomes for Breast Cancer Survivors: Measuring the Comparative Effectiveness of Survivorship Care Programs within the UCLA-LIVESTRONG Survivorship Center of Excellence”</td>
</tr>
</tbody>
</table>

**DRUG DEVELOPMENT RESEARCH PROFESSOR**

<table>
<thead>
<tr>
<th>Professor</th>
<th>Institution</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Adjei, MD, PhD</td>
<td>Roswell Park Cancer Institute</td>
<td>&quot;Development of the Toll-Like Receptor 5 Agonist, CBLB502 for Cancer Therapy&quot;</td>
</tr>
</tbody>
</table>

**TRANSLATIONAL RESEARCH PROFESSORS**

<table>
<thead>
<tr>
<th>Professor</th>
<th>Institution</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merrill J. Egorin, MD</td>
<td>University of Pittsburgh</td>
<td>“Preclinical and Clinical Studies of PARP Inhibitors as Cancer Therapy”</td>
</tr>
<tr>
<td>Mark J. Ratain, MD, FASCO</td>
<td>The University of Chicago</td>
<td>“Building a Genomic Prescribing System”</td>
</tr>
<tr>
<td>Bruce E. Johnson, MD, FASCO</td>
<td>Dana-Farber Cancer Institute</td>
<td>“Impact of Genomic Changes on the Treatment of Non-Small Cell Lung Cancer”</td>
</tr>
<tr>
<td>Everett E. Vokes, MD, FASCO</td>
<td>The University of Chicago</td>
<td>“Concomitant Chemoradiotherapy and Translational Gene Therapy Trials for Intermediate Stage Malignancies of the Lung and Head and Neck”</td>
</tr>
</tbody>
</table>

2015 CERP IN BREAST CANCER SUPPORTED BY

BCRF
Clinical Trials Participation Award

First awarded in 2003, the CTPA recognizes community-based practices to increase awareness of and participation in clinical trials among physicians.

2015 RECIPIENTS

- Cancer Care Specialists of Central Illinois
  Decatur, IL
- Blue Ridge Cancer Care
  Roanoke, VA
- Oncology Hematology Care, Inc.
  Cincinnati, OH
- Scottsdale Healthcare
  Scottsdale, AZ
- St. Joseph’s Hospital and Medical Center—Division of Gynecologic Oncology
  Phoenix, AZ
- Cone Health Cancer Center
  Greensboro, NC

2015 CTPA RECIPIENTS

- 6 Community Practices
- 128 Years Conducting Clinical Research
- 118 Full-time Oncologists
- 838 New Patients on Clinical Trial (in 2014)

SUPPORTED BY

Coalition of CANCER COOPERATIVE GROUPS
Resident Travel Award for Underrepresented Populations

First awarded in 2009, the RTA provides travel grants for residents from underrepresented populations to attend the ASCO Annual Meeting, where they will have an opportunity to meet oncologists and explore career possibilities in their area of specialty.

2015 RECIPIENTS

Olufunke Akinbobuyi, MD  
Morehouse School of Medicine

Idoroenyi Amanam, MD  
St. Mary Medical Center

Ebenezer Appah, MD  
Meharry Medical College

Frederick Doamekpor, MD  
Morehouse School of Medicine

Nancy Osuji-Oduh, MD  
Morehouse School of Medicine

Linnea Perkins, MD  
Ochsner Clinic

Sonya Reid-Lawrence, MBBS, MD  
Meharry Medical College

Oluchi Ukaegbu, MD  
Vanderbilt University Medical Center

“The RTA program was a great experience and I recommend it for every resident interested in oncology; the networking and exposure to the field of oncology will last a lifetime.”

—Brandon Blue, MD  
2014 RTA Recipient

SUPPORTED BY

Janssen Biotech, Inc.  

NOVARTIS  
Oncology
Medical Student Rotation for Underrepresented Populations

Since 2009, the MSR has supported clinical or clinical research oncology rotations for U.S. medical students from populations underrepresented in medicine who are interested in pursuing oncology as a career.

2015 RECIPIENTS

The following students are being awarded the 2015 Medical Student Rotation and will attend the 2016 ASCO Annual Meeting.

Oladapo Adeniran  
*University of Illinois at Chicago*

Cecil Benitez  
*Stanford University*  
**Supported by:** Conquer Cancer Foundation Mission Endowment

Dionisia Quiroga  
*Michigan State University*

Mario Martinez  
*University of Illinois at Chicago*

Elisa Quiroz  
*Ponce Health Sciences University*

Angel Moran  
*University of California, Davis*  
**Supported by:** Conquer Cancer Foundation Mission Endowment

Jasmine Smith  
*University of South Carolina School of Medicine Greenville*

SUPPORTED BY

[Conquer Cancer Foundation](#)  
[Genentech](#)  
[Genentech](#)  
[Genentech](#)
2014 RECIPIENTS

The following students are the 2014 Medical Student Rotation Recipients who have finished their rotations and are attending the 2015 ASCO Annual Meeting.

Oyinlolu Adeyanju
Northwestern University

Nancy Anoruo
George Washington University
Supported by: Conquer Cancer Foundation Mission Endowment

Omotola Ashorobi
The University of Illinois College of Medicine

Peter Cruz-Gordillo
University of Massachusetts Medical School
Supported by: Conquer Cancer Foundation Mission Endowment

Shekinah Nefreteri Elmore
Harvard Medical School
Supported by: Conquer Cancer Foundation Mission Endowment

Zuri Dana Hemphill
University of Cincinnati

Dembi Ophelia Huya-Kouadio
Meharry Medical College
Supported by: Conquer Cancer Foundation Mission Endowment

Maria De Lourdes Garcia-Jimenez
University of California, San Francisco

“The MSR was an amazing experience because I got to witness firsthand the daily duties of gynecologic-oncologists; the experience increased my own interest in pursuing this field.”
—Kathlene Babalola
2012 MSR Recipient

SUPPORTED BY
The Conquer Cancer Foundation has awarded more than $90 million through 1,457 grants and awards to 65 countries!
Europe & Central Asia
COUNTRIES FUNDED: 23
AWARDS: 67
TOTAL FUNDING: $1,185,798
INSTITUTIONS: 50

Asia & the Pacific
COUNTRIES FUNDED: 13
AWARDS: 111
TOTAL FUNDING: $1,965,431
INSTITUTIONS: 63

Africa & Middle East
COUNTRIES FUNDED: 17
AWARDS: 67
TOTAL FUNDING: $627,514
INSTITUTIONS: 49
ASCO has more than 35,000 members, one-third of whom practice in over 100 countries, representing the world’s largest collection of expertise and insight into the treatment of cancer. Tapping into this global network of members, ASCO International provides clinicians around the world with knowledge and training that can help them achieve better care for their cancer patients.

The Conquer Cancer Foundation is proud to support ASCO International by providing training and support for young investigators in developing countries through the IDEA and LIFe programs, by having its research grants open to the entire global community, and by supporting ASCO’s International growth with programs like the International Innovation Grant.

- **2002:** First IDEA awarded to 11 recipients
- **2010:** First LIFe awarded to an oncologist from Chile
- **2011:** First IDEA in Palliative Care awarded to 4 recipients
- **2014:** Awarded 4 inaugural International Innovation Grants

Over $2.9 Million in Training and Research Support

302 Awards

61 Developing Countries
Long-term International Fellowship

First awarded in 2010, LIFe is a one-year fellowship opportunity for early career oncologists from developing countries to deepen their relationship with an existing mentor in the United States, Canada, or Europe.

Malek Baassiri, MD
“Late Outcomes of Adult Survivors of Childhood Acute Myeloblastic Leukemia (AML) Diagnosed Between 1962-2002”
Home Institution: American University of Beirut Medical Center (Lebanon)
US Sponsoring Institution: St. Jude Children’s Research Hospital
Mentored by: Melissa Hudson, MD

Kimrom Hagos, MD
“Radiation and Chemoradiation side effect in patients with cervical cancer”
Home Institution: Black Lion Hospital, Addis Ababa University (Ethiopia)
US Sponsoring Institution: Oregon Health and Science University
Mentored by: Charles Thomas, MD

SUPPORTED BY

Since 2010, 12 early-career oncologists from 9 developing countries have received training through LIFe.
International Development and Education Award

Since 2002, IDEA has provided support for early-career oncologists in developing countries and facilitates the sharing of knowledge between these oncologists and ASCO members who serve as scientific mentors to each recipient.

Hamoud Hodeish Al-Hussaini, MD, MSc
National Oncology Center (Yemen)

Nisreen Yousef Amayiri, MBBS, MD
King Hussein Cancer Center (Jordan)

Nicoleta Zenovia Antone, MD
Ion Chiricuta Oncology Institute
Cluj-Napoca (Romania)

Shayan Kaka Salh Askary, MBBS (MBChB)
Hiwa Cancer Center (Iraq)

Claudia Maria Calderon, MD
Hospital General San Felipe (Honduras)

Jarin Chindaprasirt, MD
Chulalongkorn University (Thailand)

Rajeeb Kumar Deo, MBBS, MD
Shree Birendra Hospital (Nepal)

Nilufer Jasmine Selimah Fauzee, MBBS, MD
Central Health Laboratory, Victoria Hospital (Mauritius)

Alvaro Henrique Ingles Garces, MD
Brazilian National Cancer Institute (INCA) (Brazil)

Khaoula Mazouzi, MD
CHU Constantine—Ibn Badis Hospital (Algeria)

Vivian Paintsil, MBBS (MBChB)
Komfo Anokye Teaching Hospital (Ghana)

Herman Andres Perroud, MD, PhD
Hospital Italiano de Rosario e Instituto Genetica Experimental—UNR (Argentina)
Chepsy Cherian Philip, MBBS, MD, DM
Christian Medical College & Hospital (India)

George Pupwe, MBBS (MBChB)
Stellenbosh University-Medical School (South Africa)

Arathi Srinivasan, MBBS, MD
Kanchi Kamakoti CHILDS Trust Hospital (India)

Sule Unal, MD
Hacettepe University (Turkey)

Jule Franve Vasquez Chavez, MD
Instituto Nacional de Enfermedades Neoplasicas (Peru)

Qiongwne Zhang, MD, PhD
West China Hospital of Sichuan University (China)

New from ASCO
Journal of Global Oncology

CALL FOR PAPERS

The American Society of Clinical Oncology (ASCO), and David Kerr, MD, DSc, founding Editor-in-Chief of the Society's new Journal of Global Oncology (JGO), invite you to submit your next article to JGO.

This new online-only, open access journal fulfills a growing need for content describing the array of challenges health care professionals in resource constrained settings face in conducting research and caring for patients with cancer. First articles will publish third quarter 2015.

Article types that will be considered for publication include original reports, review articles, commentaries, correspondence/replies, special articles, and editorials.

For more information on submitting to Journal of Global Oncology, please visit GlobalOncologyJournal.org.

SUPPORTED BY

AstraZeneca
Bayer
Conquer Cancer Foundation
Roche
Takeda Oncology

*As of April 29, 2015

The American Society of Clinical Oncology (ASCO), and David Kerr, MD, DSc, founding Editor-in-Chief of the Society's new Journal of Global Oncology (JGO), invite you to submit your next article to JGO.

This new online-only, open access journal fulfills a growing need for content describing the array of challenges health care professionals in resource constrained settings face in conducting research and caring for patients with cancer. First articles will publish third quarter 2015.

Article types that will be considered for publication include original reports, review articles, commentaries, correspondence/replies, special articles, and editorials.

For more information on submitting to Journal of Global Oncology, please visit GlobalOncologyJournal.org.

SUPPORTED BY

AstraZeneca
Bayer
Conquer Cancer Foundation
Roche
Takeda Oncology

*As of April 29, 2015

The American Society of Clinical Oncology (ASCO), and David Kerr, MD, DSc, founding Editor-in-Chief of the Society's new Journal of Global Oncology (JGO), invite you to submit your next article to JGO.

This new online-only, open access journal fulfills a growing need for content describing the array of challenges health care professionals in resource constrained settings face in conducting research and caring for patients with cancer. First articles will publish third quarter 2015.

Article types that will be considered for publication include original reports, review articles, commentaries, correspondence/replies, special articles, and editorials.

For more information on submitting to Journal of Global Oncology, please visit GlobalOncologyJournal.org.

SUPPORTED BY

AstraZeneca
Bayer
Conquer Cancer Foundation
Roche
Takeda Oncology

*As of April 29, 2015

The American Society of Clinical Oncology (ASCO), and David Kerr, MD, DSc, founding Editor-in-Chief of the Society's new Journal of Global Oncology (JGO), invite you to submit your next article to JGO.

This new online-only, open access journal fulfills a growing need for content describing the array of challenges health care professionals in resource constrained settings face in conducting research and caring for patients with cancer. First articles will publish third quarter 2015.

Article types that will be considered for publication include original reports, review articles, commentaries, correspondence/replies, special articles, and editorials.

For more information on submitting to Journal of Global Oncology, please visit GlobalOncologyJournal.org.

SUPPORTED BY

AstraZeneca
Bayer
Conquer Cancer Foundation
Roche
Takeda Oncology

*As of April 29, 2015

The American Society of Clinical Oncology (ASCO), and David Kerr, MD, DSc, founding Editor-in-Chief of the Society's new Journal of Global Oncology (JGO), invite you to submit your next article to JGO.

This new online-only, open access journal fulfills a growing need for content describing the array of challenges health care professionals in resource constrained settings face in conducting research and caring for patients with cancer. First articles will publish third quarter 2015.

Article types that will be considered for publication include original reports, review articles, commentaries, correspondence/replies, special articles, and editorials.

For more information on submitting to Journal of Global Oncology, please visit GlobalOncologyJournal.org.

SUPPORTED BY

AstraZeneca
Bayer
Conquer Cancer Foundation
Roche
Takeda Oncology

*As of April 29, 2015

The American Society of Clinical Oncology (ASCO), and David Kerr, MD, DSc, founding Editor-in-Chief of the Society's new Journal of Global Oncology (JGO), invite you to submit your next article to JGO.

This new online-only, open access journal fulfills a growing need for content describing the array of challenges health care professionals in resource constrained settings face in conducting research and caring for patients with cancer. First articles will publish third quarter 2015.

Article types that will be considered for publication include original reports, review articles, commentaries, correspondence/replies, special articles, and editorials.

For more information on submitting to Journal of Global Oncology, please visit GlobalOncologyJournal.org.

SUPPORTED BY

AstraZeneca
Bayer
Conquer Cancer Foundation
Roche
Takeda Oncology

*As of April 29, 2015

The American Society of Clinical Oncology (ASCO), and David Kerr, MD, DSc, founding Editor-in-Chief of the Society's new Journal of Global Oncology (JGO), invite you to submit your next article to JGO.

This new online-only, open access journal fulfills a growing need for content describing the array of challenges health care professionals in resource constrained settings face in conducting research and caring for patients with cancer. First articles will publish third quarter 2015.

Article types that will be considered for publication include original reports, review articles, commentaries, correspondence/replies, special articles, and editorials.

For more information on submitting to Journal of Global Oncology, please visit GlobalOncologyJournal.org.

SUPPORTED BY

AstraZeneca
Bayer
Conquer Cancer Foundation
Roche
Takeda Oncology

*As of April 29, 2015

The American Society of Clinical Oncology (ASCO), and David Kerr, MD, DSc, founding Editor-in-Chief of the Society's new Journal of Global Oncology (JGO), invite you to submit your next article to JGO.

This new online-only, open access journal fulfills a growing need for content describing the array of challenges health care professionals in resource constrained settings face in conducting research and caring for patients with cancer. First articles will publish third quarter 2015.

Article types that will be considered for publication include original reports, review articles, commentaries, correspondence/replies, special articles, and editorials.

For more information on submitting to Journal of Global Oncology, please visit GlobalOncologyJournal.org.

SUPPORTED BY

AstraZeneca
Bayer
Conquer Cancer Foundation
Roche
Takeda Oncology

*As of April 29, 2015

The American Society of Clinical Oncology (ASCO), and David Kerr, MD, DSc, founding Editor-in-Chief of the Society's new Journal of Global Oncology (JGO), invite you to submit your next article to JGO.

This new online-only, open access journal fulfills a growing need for content describing the array of challenges health care professionals in resource constrained settings face in conducting research and caring for patients with cancer. First articles will publish third quarter 2015.

Article types that will be considered for publication include original reports, review articles, commentaries, correspondence/replies, special articles, and editorials.

For more information on submitting to Journal of Global Oncology, please visit GlobalOncologyJournal.org.

SUPPORTED BY

AstraZeneca
Bayer
Conquer Cancer Foundation
Roche
Takeda Oncology

*As of April 29, 2015

The American Society of Clinical Oncology (ASCO), and David Kerr, MD, DSc, founding Editor-in-Chief of the Society's new Journal of Global Oncology (JGO), invite you to submit your next article to JGO.

This new online-only, open access journal fulfills a growing need for content describing the array of challenges health care professionals in resource constrained settings face in conducting research and caring for patients with cancer. First articles will publish third quarter 2015.

Article types that will be considered for publication include original reports, review articles, commentaries, correspondence/replies, special articles, and editorials.

For more information on submitting to Journal of Global Oncology, please visit GlobalOncologyJournal.org.

SUPPORTED BY

AstraZeneca
Bayer
Conquer Cancer Foundation
Roche
Takeda Oncology

*As of April 29, 2015

The American Society of Clinical Oncology (ASCO), and David Kerr, MD, DSc, founding Editor-in-Chief of the Society's new Journal of Global Oncology (JGO), invite you to submit your next article to JGO.

This new online-only, open access journal fulfills a growing need for content describing the array of challenges health care professionals in resource constrained settings face in conducting research and caring for patients with cancer. First articles will publish third quarter 2015.

Article types that will be considered for publication include original reports, review articles, commentaries, correspondence/replies, special articles, and editorials.

For more information on submitting to Journal of Global Oncology, please visit GlobalOncologyJournal.org.
International Innovation Grant

Now on its second year, the International Innovation Grant provides funding in support of novel and innovative projects with the potential to advance cancer control in low- and middle-income countries.

**College of Medicine, University of Ibadan (Nigeria)**

“Enhancing Health Resource Capacity to Prevent Cervical Cancer by Leveraging on HIV/AIDS Care and Treatment Infrastructure”

**Principal Investigator:** Olutosin Alaba Awolude, MBBS, MS

**Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (Mexico)**

“A breast health educational program to increase breast cancer awareness among adolescents and their female relatives in low-income communities through intergenerational learning”

**Principal Investigator:** Yanin Chávarri Guerra, MD, MSc

**Tata Medical Center (India)**

“Mobile Short Message Service (SMS) alerts for reducing the toxicity and improving protocol compliance during cancer chemotherapy: A randomized controlled trial”

**Principal Investigator:** Tanuj Chawla, MBBS, MD

**The Oncology Institute “Prof. Dr. Ion Chiricuta” (Romania)**

“A multidisciplinary breast tumor board telemedicine web-based platform to improve the appropriateness and implementation of treatment recommendations in small, remote cancer centers in Romania”

**Principal Investigator:** Alexandru Eugen Eniu, MD, PhD

**Hutchinson Centre Research Institute of Uganda (Uganda)**

“Linking Cervical Cancer Screening in HIV Clinics to Tertiary Cancer Care in Uganda”

**Principal Investigator:** Noleb Mugume Mugisha, MPH, MBChB

“The development of novel, resource-appropriate, sustainable, and transferrable programs aimed at improving cancer control in low- and middle-income countries] is the mission of the Conquer Cancer Foundation International Innovation Grants. The research studies proposed by the five awardees are perfect exemplars of this mission.”

—Matthew D. Galsky, MD, Chair International Innovation Grant Subcommittee

**SUPPORTED BY**
Merit Awards*

Awarded to oncology trainees who are first authors on high-scoring abstracts selected for presentation at the ASCO Annual Meeting.

Tarek Abdel-Fatah, MB ChB, PhD, MSc
Nottingham University City Hospital NHS Trust

Wassim Abida, MD, PhD (2014 YIA)
Memorial Sloan Kettering Cancer Center

Melissa Accordino, MD (2014 YIA)
New York Presbytarian Columbia

Anoshe Afghahi, MD, MPH
Stanford University Medical Center

Arun Azad, MBBS, PhD, FRACP
British Columbia Cancer Agency

Hatem Azim, MD, PhD
Institut Jules Bordet

Myron Best, BMed
VU University Medical Center

Pierre Camateros, MD, PhD
University of British Columbia

Wen Yee Chay, MBBS, MRCP
British Columbia Cancer Agency

Yin Ting Cheung, PhD, BSc (Pharm)
St. Jude Children’s Research Hospital

Dai Chihara, MD, PhD
The University of Texas MD Anderson Cancer Center

Victoria Chiou, MD
National Cancer Institute

Erin Cobain, MD
University of Michigan Health System

Natalie Cook, MD, PhD
Princess Margaret Cancer Centre

BRADLEY STUART BELLER SPECIAL MERIT AWARD

This award is given to the fellow who has the highest ranking abstract overall in the Merit Award category as determined by the Scientific Program Committee. The award is funded through the Bradley Stuart Beller Endowment Fund.

Maria Jose de Miguel Luken, MD
The Institute of Cancer Research and The Royal Marsden Hospital

“A pharmacokinetic (PK) and pharmacodynamic (PD) biomarker-driven phase I study of intermittent, low dose intensity schedules of the dual MEK/RAF inhibitor, RO5126766 (RO) in patients (pts) with advanced solid tumors.”

Clinical Science Symposium, Abstract 104
Sunday, May 31, 9:45 AM–11:15 AM

Francesco Crea, MD, PhD
British Columbia Cancer Agency

Jennifer Crozier, MD
Mayo Clinic

May Daher, MD
The University of Texas MD Anderson Cancer Center

Yasir Elamin, MD (2015 YIA)
Education Centre Beaumont Hospital

Lawson Eng, MD
Princess Margaret Cancer Centre

*As of April 6, 2015.
Zeynep Eroglu, MD
City of Hope

Bishoy Faltas, MD (2015 YIA)
Weill Cornell Medical College

Andre Fay, MD
Dana-Farber Cancer Institute

Pauline Funchain, MD
Cleveland Clinic

Daniel Goldstein, MD
Winship Cancer Institute, Emory University

Wilson Gonsalves, MD
Mayo Clinic

Emily Guerard, MD
The University of North Carolina at Chapel Hill

Anasuya Gunturi, MD, PhD
Beth Israel Deaconess Medical Center

Jason Hearn, MD
Cleveland Clinic

Yanfeng Hu, MD
Nanfang Hospital, Southern Medical University

Kathryn Hudson, MD
Duke University Medical Center

Scott Huntington, MD, MPH
Abramson Cancer Center of the University of Pennsylvania

Haruka Itakura, MD
Stanford University Medical Center

Kevin Jao, MD, FRCPC
Princess Margaret Cancer Centre

John Kaczmar, MD
Temple University/Fox Chase Cancer Center

Reva Kakkar Basho, MD
The University of Texas MD Anderson Cancer Center

Shumei Kato, MD
The University of Texas MD Anderson Cancer Center

Bridget Leventhal Special Merit Award

This award is given to the fellow who submitted the top abstract in Pediatric Oncology as determined by the Scientific Program Committee.

Mark Applebaum, MD
University of Chicago
“Second malignancies in neuroblastoma patients: A report from the International Neuroblastoma Risk Group.”

Poster Discussion Session, Abstract 10019
Sunday, May 31, 8:00 AM-11:30 AM, 11:30 AM-12:45 PM

Yuki Katsuya, MD
National Cancer Center Hospital

Sharon Kim, BA
Mayo Clinic

Vadim Koshkin, MD
University of Michigan

Jeremy Lewin, MBBS, FRACP
Peter MacCallum Cancer Centre

Stephanie Lheureux, MD, PhD
Princess Margaret Cancer Centre

Bob Li, MBBS, MPH, FRACP (2015 YIA)
Memorial Sloan Kettering Cancer Center

Xuewen Liu, MD, PhD
Columbia University Medical Center & Sun Yat-sen University Cancer Center

Kah Poh Loh, MBBCh
Baystate Medical Center

David Lorente, MD
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
Arin Madenci, MD, MPH  
Brigham and Women’s Hospital

Parag Mahale, MBBS, MPH  
The University of Texas MD Anderson Cancer Center

Steven Maron, MD  
University of Chicago

Jonathan Marron, MD  
Dana-Farber Cancer Institute, Boston Children's Hospital

Deborah Marshall, MD  
University of California, San Diego

Kara Maxwell, MD, PhD (2015 YIA)  
University of Pennsylvania Perelman School of Medicine

Maria May, MD  
IBYME-CONICET

Alvaro Menendez, MD  
Roger Williams Medical Center/Boston University School of Medicine

Vasiliki Michalarea, MBBS  
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust

Demytra Mitsis, MD  
Roswell Park Cancer Institute

Amr Mohamed, MD  
Morehouse School of Medicine

Jarushka Naidoo, MB BCh BAO, MRCPI  
Memorial Sloan Kettering Cancer Center

Hiten Naik, BHS (Hon)  
University of Toronto

Terence Ng, BSc (Pharm) Hons  
National University of Singapore

David Page, MD (2015 YIA)  
Memorial Sloan Kettering Cancer Center

Shalu Pahuja, MD  
University of Pittsburgh Medical Center

Haeseong Park, MD, MPH  
The University of Texas MD Anderson Cancer Center

YaoYao Pollock, MD  
Johns Hopkins University School of Medicine

Erqi Pollom, MD  
Stanford University Medical Center

---

**JAMES B. NACHMAN ASCO JUNIOR FACULTY AWARD IN PEDIATRIC ONCOCYLOGY**

This award, established in memory of James B. Nachman, MD, Professor of Pediatrics at the University of Chicago, is given each year to a junior faculty member who submits the highest-scoring abstract in pediatric oncology for the ASCO Annual Meeting as determined by the ASCO Scientific Program Committee. The Award is funded through the James B. Nachman Pediatric Oncology Fund.

**Sébastien Héritier, MD**  
Versailles University & APHP, Trousseau hospital

“Langerhans cell histiocytosis in children: Correlation of BRAFstatus with clinical characteristic.”

Oral Abstract Session: Pediatric Oncology I, Abstract 10003  
Saturday, May 30, 3:00 PM-6:00 PM
PAIN AND SYMPTOM MANAGEMENT
SPECIAL MERIT AWARD
This award is given to the fellow who submitted the top abstract in Pain Management Research as determined by the Scientific Program Committee.

Ryan Nipp, MD
Dana Farber Cancer Institute
“Quality of life and mood in patients with advanced cancer: Associations with prognostic understanding and coping style.”
Poster Discussion Session, Abstract 9517
Saturday, May 30, 1:15 PM-4:45 PM, 4:45 PM-6:00 PM
Stephanie Wheeler, PhD  
The University of North Carolina at Chapel Hill

Michelle Wilson, MBChB, FRACP  
Princess Margaret Cancer Centre

Dimitrios Zardavas, MD  
Breast International Group

Nicholas Zdenkowski, BMed  
ANZ Breast Cancer Trials Group

Tian Zhang, MD  
Duke University Medical Center

Maria Zlobinsky Rubinstein, MD  
Montefiore Medical Center

SUPPORTED BY

The Bradley Stuart Beller Endowment Fund  
Jackson G. Simpson

Also Supported by

Oncology Trainee Travel Award

The OTTA supports the continuing education and professional development of trainee oncologists by providing them individual travel grant to defray travel expenses for attending the ASCO Annual Meeting. In 2015, Conquer Cancer Foundation is awarding 64 OTTAs.

“Thank you so much for supporting my very first visit to the ASCO Annual Meeting. I learned so many things and met several key people that will be important as I shape my path as a clinician/researcher.”

—2014 OTTA Recipient

2015 Grant & Award Recipients  31
Conquer Cancer Foundation Board of Directors

CHAIR
W. Charles Penley, MD, FASCO
Tennessee Oncology

CHAIR EMERITUS
Martin J. Murphy, DMedSc, PhD, FASCO
AlphaMed Consulting, LLC

Raj Mantena, RPh

TREASURER
Gabriel N. Hortobagyi, MD, FACP, FASCO
The University of Texas MD Anderson Cancer Center

Thomas A. Marsland, MD, FASCO
21st Century Oncology

SECRETARY
Thomas G. Roberts Jr., MD
Farallon Capital Management, LLC

Robert J. Mayer, MD, FASCO
Dana-Farber Cancer Institute

DIRECTORS
Lawrence H. Einhorn, MD, FASCO
Indiana University Simon Cancer Center

Steven T. Rosen, MD, FACP
City of Hope

John H. Glick, MD, FASCO
Abramson Cancer Center of the University of Pennsylvania

Aaron A. Sasson
Lanetix

Michael L. Gordon, JD
Angelo, Gordon & Co.

Sandra M. Swain, MD, FACP, FASCO
Washington Cancer Institute, MedStar Washington Hospital

Claire A. Huang

Beth Y. Karlan, MD
Cedars-Sinai Medical Center

Conquer Cancer Foundation

ASCO PRESIDENT, ex-officio
Peter P. Yu, MD, FACP, FASCO
Palo Alto Medical Foundation

Conquer Cancer Foundation Board of Directors

CHAIR
W. Charles Penley, MD, FASCO
Tennessee Oncology

CHAIR EMERITUS
Martin J. Murphy, DMedSc, PhD, FASCO
AlphaMed Consulting, LLC

Raj Mantena, RPh

TREASURER
Gabriel N. Hortobagyi, MD, FACP, FASCO
The University of Texas MD Anderson Cancer Center

Thomas A. Marsland, MD, FASCO
21st Century Oncology

SECRETARY
Thomas G. Roberts Jr., MD
Farallon Capital Management, LLC

Robert J. Mayer, MD, FASCO
Dana-Farber Cancer Institute

DIRECTORS
Lawrence H. Einhorn, MD, FASCO
Indiana University Simon Cancer Center

Steven T. Rosen, MD, FACP
City of Hope

John H. Glick, MD, FASCO
Abramson Cancer Center of the University of Pennsylvania

Aaron A. Sasson
Lanetix

Michael L. Gordon, JD
Angelo, Gordon & Co.

Sandra M. Swain, MD, FACP, FASCO
Washington Cancer Institute, MedStar Washington Hospital

Claire A. Huang

Beth Y. Karlan, MD
Cedars-Sinai Medical Center

Conquer Cancer Foundation

ASCO PRESIDENT, ex-officio
Peter P. Yu, MD, FACP, FASCO
Palo Alto Medical Foundation
PRESIDENT
Peter P. Yu, MD, FACP, FASCO
Palo Alto Medical Foundation

PRESIDENT-ELECT
Julie M. Vose, MD, MBA, FASCO
University of Nebraska Medical Center and Fred and Pamela Buffet Cancer Center

IMMEDIATE PAST PRESIDENT
Clifford A. Hudis, MD, FACP
Memorial Sloan Kettering Cancer Center

TREASURER
Susan L. Cohn, MD
University of Chicago

CHIEF EXECUTIVE OFFICER, ex-officio
Allen S. Lichter, MD, FASCO
American Society of Clinical Oncology

CCF CHAIR, ex-officio
W. Charles Penley, MD, FASCO
Tennessee Oncology

DIRECTORS
Smita Bhatia, MD, MPH (1996 YIA)
University of Alabama at Birmingham School of Medicine

Charles D. Blanke, MD, FACP, FASCO
Oregon Health & Science University Knight Cancer Institute

Linda D. Bosserman, MD, FACP
Wilshire Oncology Medical Group, Inc.

Walter J. Curran, Jr., MD, FACP
Winship Cancer Institute of Emory University

Stephen S. Grubbs, MD
Medical Oncology Hematology Consultants, PA

Paulo Hoff, MD, FACP
ICESP—Instituto do Câncer do Estado de São Paulo

Hagop M. Kantarjian, MD
The University of Texas MD Anderson Cancer Center

David Khayat, MD, PhD, FASCO
Pitié-Salpêtrière Hospital

Gary H. Lyman, MD, MPH, FASCO
Hutchinson Institute for Cancer Outcomes Research

Neal J. Meropol, MD, FASCO
University Hospitals Case Medical Center & Case Western Reserve University

Therese M. Mulvey, MD, FASCO
Southcoast Centers for Cancer Care

Carolyn D. Runowicz, MD, FASCO
Florida International University

Lillian L. Siu, MD, FRCPc
Princess Margaret Hospital/University of Toronto

Eric P. Winer, MD, FASCO
Dana-Farber Cancer Institute
Grants Selection Committee

CHAIR
Mark Levis, MD, PhD (2003 CDA, 2008 ACRA in Hematologic Malignancies)

CHAIR-ELECT
Eduardo Sotomayor, MD

IMMEDIATE PAST CHAIR
Pasi Jänne, MD, PhD (2001 YIA)

FOUNDATION BOARD LIASON
Robert Mayer, MD, FASCO

ASCO BOARD LIASON
Smita Bhatia, MD, MPH (1996 YIA)
Sylvia Adams, MD (2003 YIA, 2004 CDA)
Christina Annunziata, MD, PhD
D. Ross Camidge, MD, PhD
William Carroll, MD (1988 YIA)
Arnab Chakravarti, MD
Sarat Chandarlapaty, MD, PhD (2007 YIA)
Richard Chappell, PhD
Toni Choueiri, MD (2010 CDA)
Suzanne Dahlberg, PhD
Karim Fizazi, MD, PhD
Thomas Flaig, MD
Matt Galsky, MD
William Barry, PhD
Cynthia Chauhan, MSW
Susan Domcheck, MD
Elizabeth Garrett-Mayer, PhD
Sharon Giordano, MD
Tari King, MD
Mary Lou Smith, JD, MBA
Richard Zellars, MD

ADVANCED CLINICAL RESEARCH AWARD SUBCOMMITTEE

CHAIR

ADVANCED CLINICAL RESEARCH AWARD

Ingo Mellinghoff, MD (2003 YIA, 2009 ACRA in Glioma)
Soheil Meshinchi, MD, PhD
Jeffrey Meyerhardt, MD, MPH (2003 CDA)
Elizabeth Mittendorf, MD, PhD
Shanu Modi, MD (2009 ACRA in Breast Cancer)
Supriya Mohile, MD, MS (2004 YIA)
Yael Mosse, MD (2003 YIA, 2004 CDA)
Sattva Neelapu, MD (2006 CDA)
Daniel Normolle, PhD
Javier Pinilla-Ibarz, MD (2003 YIA, 2007 CDA)
Mary Redman, PhD
Richard Riedel, MD
Gregory Riely, MD, PhD (2007 YIA)
Tanguy Seiwert, MD (2006 YIA)
Manish Shah, MD (2001 YIA, 2003 CDA)
Frances Shepherd, MD
Alexi Wright, MD, MPH (2009 YIA)
Jason Wright, MD

CLINICAL TRIALS PARTICIPATION AWARD SUBCOMMITTEE

CHAIR
Stephen Grubbs, MD

CLINICAL TRIALS PARTICIPATION AWARD

Gary Unzeitig, MD (2009, 2014 CTPA)
Johanna Bendell, MD
Mehmet Copur, MD, FACP (2010 CORG, 2010 CTPA)
Alan Lyss, MD (2010 CTPA)
DIVERSITY IN ONCOLOGY SUBCOMMITTEE

CHAIR
Jill Lacy, MD

Pascal Jean-Pierre, PhD, MPH
Cesar Santa-Maria, MD (2010 RTA, 2014 Special Merit Award)
Sandra Wong, MD, MS
Syed Yousuf Zafar, MD, MHS

INTERNATIONAL INNOVATION GRANT SUBCOMMITTEE

CHAIR
Matthew Galsky, MD

PAST CHAIR
Anees Chagpar, MD
Linus Chuang, MD
Brenda Edwards, PhD
Susan Miesfeldt, MD
Olatoyosi Odenike, MD (2003 CDA)
Ian Olver, MD, PhD, FRACP
Josep Tabernero, MD, PhD
Cynthia Vinson, PhD, MPA

LONG-TERM INTERNATIONAL FELLOWSHIP SUBCOMMITTEE

CHAIR
Lillian Siu, MD, FASCO

Alex Adjei, MD, PhD (2012 DDRP)
Raghunadharaao Digumarti, MD, DM, MBBS
Andres Forero-Tores, MD
Daniel Hayes, MD, FASCO
Tony Mok, MD

COMPARATIVE EFFECTIVENESS RESEARCH PROFESSORSHIP SUBCOMMITTEE

CHAIR
Gary H. Lyman, MD, MPH, FACP, FRCP (Edin), FASCO

Thomas Buchholz, MD
Angela DeMichele, MD, MSCE (1998 YIA)
Judy Garber, MD, MPH
Lisa Newman, MD, MPH
Jeffrey Peppercorn, MD, MPH (2007 CDA)
Antonio Wolff, MD, FACP, FASCO

INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD WORKING GROUP

CHAIR
Jean René Clemenceau, MD

PAST CHAIR
Roselle B. de Guzman, MD (2006 IDEA)

CHAIR-ELECT
Lidia Schapira, MD

PERMANENT MEMBER
Lawrence H. Einhorn, MD, FASCO

Clement A. Adebamowo, MD, ScD (2003 IDEA)
Francisco Gutierrez Delgado, MD, PhD, FACP
Tianhong (Tina) Li, MD, PhD
Daniela Morales-Espinosa, MD (2007 IDEA)
Layth Mula-Hussain, MD, MSc (2005 IDEA)
Nadim Nimeh, MD
Philip Agop Philip, MD, PhD, FRCP
Navneet Singh, MD, DM, FACP, FCCP (2008 IDEA)

MERIT AWARDS

The Merit Awards are selected by members of the ASCO Scientific Program Committee.
Conquer Cancer Foundation Staff

EXECUTIVE OFFICE
Nancy R. Daly, MS, MPH, Executive Director and Chief Philanthropic Officer
Jamie Grandison, Governance Specialist
Vaishali Revollo, Manager, Campaign & Special Projects

ANNUAL GIVING DIVISION
Russell Williams, MBA, Director, Annual Giving
April Avant, Online Fundraising Manager
Katie Heller, Direct Marketing Administrator
Karen Jupiter, Annual Giving Manager
Tyler Woods, Fundraising Coordinator

DONOR ENGAGEMENT AND CAMPAIGN DIVISION
Matthew Lee, JD, Director, Donor Engagement and Campaign
Jarret Christensen, Manager, Donor Events
Elizabeth Hagen, Manager, Donor Relations
Chrisanthe Theodorakakis, Donor Relations Coordinator
Laurie Whitaker, Prospect Researcher

GRANTS & AWARDS AND FOUNDATION GIVING DIVISION
Eileen Melnick, Director, Grants & Awards and Foundation Giving
Dean Frohlich, PhD, Scientific Review Officer
Candice Griffin, Senior Program Manager
Sonia McStay, MBA, Senior Program Manager
Cooper Pate, Program Administrator
Susan Sandler, MBA, Major Gifts Officer, Foundations

OPERATIONS AND CORPORATE GIVING DIVISION
Adrien Dickerson, MBA, Director, Operations and Corporate Giving
Reese Teasley, Associate Director, Operations
Sushmita Sen, Associate Director, Health Care Companies
Andrea Ridenour, Associate Director, Non-Health Care Companies
Quiana Cadlett, Manager, Raiser’s Edge Database
Marie Davis, Contract Administrator
Melissa Gilbert, Grant Compliance Coordinator
Gina Grantham, Grants Administrator
Gray Ladd, Manager, Grant Compliance
Sarah Mihalus, Grants Coordinator
Virginia Moncada, Administrative Coordinator
Drew Steele, Administrative Associate

The Conquer Cancer Foundation would also like to acknowledge the support of staff from ASCO’s International Affairs Department and from the Education, Science, and Professional Development Department.

*As of April 29, 2015
While 1 in 2 people will get cancer in their lifetime, 2 in 3 will survive it.* And that’s a testament to the progress you’ve helped forge as we work to uncover new therapies, fund young investigators, and pool the knowledge of practicing oncologists like you. Together, we’re making it harder for cancer to survive.

Join The Campaign To Conquer Cancer at conquer.org/progress.

#ConquerCancer

Conquer Cancer Foundation
Grants & Awards Program Supporters*

ADVANCED CLINICAL RESEARCH AWARD IN BREAST CANCER
Breast Cancer Research Foundation®

CAREER DEVELOPMENT AWARD
Amgen
Astellas
AstraZeneca
Breast Cancer Research Foundation®
Conquer Cancer Foundation Mission Endowment
Genentech BioOncology™
GlaxoSmithKline Oncology
Lilly
Michael's Mission
Roche
Takeda Oncology

CLINICAL TRIALS PARTICIPATION AWARDS
Coalition of Cancer Cooperative Groups

COMPARATIVE EFFECTIVENESS RESEARCH PROFESSORSHIP IN BREAST CANCER
Breast Cancer Research Foundation®

DRUG DEVELOPMENT RESEARCH PROFESSORSHIP
Sanofi Oncology

INTERNATIONAL DEVELOPMENT AND EDUCATION AWARDS
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Conquer Cancer Foundation
Roche
Takeda Oncology

INTERNATIONAL INNOVATION GRANT
ASCO International
AstraZeneca
Roche

LONG-TERM INTERNATIONAL FELLOWSHIP
Conquer Cancer Foundation
Gilead Sciences, Inc.
Roche

MEDICAL STUDENT ROTATION FOR UNDERREPRESENTED POPULATIONS
Conquer Cancer Foundation Mission Endowment
Eisai Inc.
Genentech BioOncology™
Lilly

MERIT AWARDS
Amgen
ASCO Cancer Research Committee
AstraZeneca
Bradley Stuart Beller Endowment Fund
Conquer Cancer Foundation Mission Endowment
Gilead Sciences, Inc.
Incyte Corporation
Jackson G. Simpson
Kidney Cancer Association
Lilly
Novartis Oncology
Onyx Pharmaceuticals
Takeda Oncology
TESARO

ONCOLOGY TRAINEE TRAVEL AWARDS
Takeda Oncology

RESIDENT TRAVEL AWARD FOR UNDERREPRESENTED POPULATIONS
Janssen Biotech, Inc.
Novartis Oncology

*Includes supporters of active multi-year grants; listing as of April 29, 2015.
YOUNG INVESTIGATOR AWARD
AbbVie
American Association for Cancer Research
Amgen
Anonymous
ASCO and Conquer Cancer Foundation Boards of Directors
ASCO Cancer Research Committee
ASCO State Affiliate Council and ASCO Clinical Practice Committee
AstraZeneca
Boehringer Ingelheim Pharmaceuticals, Inc.
Breast Cancer Research Foundation®
Celgene Corporation
The Cholangiocarcinoma Foundation
Conquer Cancer Foundation
Conquer Cancer Foundation Women Who Conquer Cancer
Eisai Inc.
Ethicon
Genentech BioOncology™
Gilead Sciences, Inc.
Incyte Corporation
Janssen Biotech, Inc.
The John and Elizabeth Leonard Family Foundation
Journal of Clinical Oncology
Kidney Cancer Association
Lilly
Merck Oncology
Novartis Oncology
Onyx Pharmaceuticals
Susan K. Parsons, MD, and Walter Armstrong
Pfizer Oncology
The Reid R. Sacco Adolescent and Young Adult Alliance
Roche
The Scopus Foundation
Young A. Sohn and Mark Armenante
Strike 3 Foundation
Takeda Oncology
The WWWW Foundation, Inc. (QuadW) and The Sarcoma Fund of the QuadW Foundation of Communities Foundation of Texas
Top Donor Recognition Awards

The Conquer Cancer Foundation gratefully acknowledges the continuing support of the many generous foundations and organizations that make the Society’s work possible. The Conquer Cancer Foundation honors the following supporters, whose contributions during the past year have allowed the Foundation to strengthen and improve its important cancer research and education initiatives in support of the Society.

Astellas
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Breast Cancer Research Foundation®
Cancer Treatment Centers of America®
Genentech BioOncology™
Raj Mantena, RPh
Merck Oncology
Pfizer Oncology
Takeda Oncology

* List reflects contributions received between April 1, 2014 and March 31, 2015
We Run
We Ride
We Conquer

#WeConquerCancer

Fundraising is easy with #WeConquerCancer. There are so many fun and creative ways to raise money for The Campaign to Conquer Cancer—ask for donations instead of gifts for your birthday, run a race, host an event—it is all up to you.

Start today at WeConquerCancer.net!